US Market News
4月前
Accessible Health Platforms Gain Scale Across $6T Health and Wellness MarketFebruary 13, 2026 11:26 AM
PR Newswire (US)
ISSUED ON BEHALF OF DOSEOLOGY SCIENCES INC.VANCOUVER, BC, Feb. 13, 2026 /PRNewswire/ -- Equity-Insider.com News Commentary – The global health and wellness sector is entering 2026 on a trajectory toward $6 trillion in annual consumer spending, underpinned by rising demand for functional products that deliver measurable outcomes beyond basic nutrition[1]. At the same time, the FDA's updated "Healthy" labeling framework and stricter clean-label regulations are reshaping how brands formulate and position consumer health products, pushing innovation toward sugar-free, preservative-free, and portable delivery systems[2]. Five companies operating along that accessibility curve include Doseology Sciences (CSE: MOOD), Amneal Pharmaceuticals (NASDAQ: AMRX), Prestige Consumer Healthcare (NYSE: PBH), Viking Therapeutics (NASDAQ: VKTX), and Insulet (NASDAQ: PODD).A recent Global Wellness Summit forecast identifies personalized oral delivery and functional reformulation as defining themes for 2026, as consumers prioritize convenience, clinical credibility, and precise dosing[3]. That convergence of wellness innovation and broader healthcare accessibility is channeling capital toward platforms built around scalable, consumer-centric health delivery[4].Doseology Sciences Inc. (CSE: MOOD) (OTCPK: DOSEF) (FSE: VU70) recently launched pilot production of caffeine-based energy pouches in January 2026, marking the Feed That Brain brand's entry into the fast-expanding oral pouch category. Based in Kelowna, British Columbia, Doseology Sciences is producing nicotine-free pouches that deliver measured caffeine doses in a compact, portable format, drawing on the same consumer shift that turned tobacco-free nicotine pouches into a multibillion-dollar segment.The pilot pouches skip the sugar, carbonation, and liquid volume found in conventional energy drinks. A direct-to-consumer test phase is planned to collect customer feedback and operational data ahead of any broader commercial launch."This pilot reflects a disciplined and intentional approach to evaluating new product formats within our platform," said Tim Corkum, President and COO of Doseology Sciences. "Feed That Brain brings a strong foundation in functional product design, and this initiative allows us to assess caffeine-based, pouch-format energy delivery under a measured and compliant framework."The energy pouch program grew out of Doseology Sciences' August 2025 acquisition of the Feed That Brain brand for $400,000, paid entirely through stock issuance. Feed That Brain, a Toronto-based cognitive health label founded by Forbes-recognized entrepreneur Rena R. Dempsey, built its reputation on functional gummies and nootropic supplements designed to support mental performance.Doseology Sciences also secured Joseph Mimran as Strategic Advisor under a three-year agreement valued at $400,000 in restricted share units. Mimran co-founded Alfred Sung, founded Club Monaco (later acquired by Ralph Lauren), and created the Joe Fresh retail brand. He cited the company's product development process and attention to regulatory compliance as reasons for joining.Two large market tailwinds support the strategy. Grand View Research projects the global energy drinks market will grow from $79.4 billion in 2024 to $125.1 billion by 2030. The nicotine pouch segment is forecast to climb from $5.4 billion in 2024 to over $25 billion by 2030, reflecting a 29.6% annual growth rate. Rising consumer concern over sugar intake and beverage overconsumption continues to push demand toward alternative caffeine delivery methods.Doseology Sciences currently distributes Gummies and Collagen products under the Feed That Brain brand across close to 500 Canadian retail locations. Its U.S. subsidiary, Doseology USA Inc., established earlier this year, is working on pouches that blend caffeine with nootropics and adaptogens. The leadership team now includes CEO Chris Jackson, President and COO Tim Corkum, and Strategic Go-to-Market Advisor Patrick Sills.CONTINUED... Read this and more news for Doseology Sciences at:https://equity-insider.com/2025/12/19/what-comes-after-cigarettes-vapes-and-energy-drinks/Amneal Pharmaceuticals (NASDAQ: AMRX) introduced a new brand identity reflecting its evolution into a diversified global biopharmaceutical leader, anchored by a refreshed logo symbolizing the trust placed in healthcare providers and the real-world impact of each prescription. The company now delivers more than 160 million prescriptions annually across a portfolio of over 290 medicines."As Amneal has grown and diversified, our brand needed to evolve with us," said Chirag Patel, Co-Founder and Co-CEO of Amneal Pharmaceuticals. "This new brand reflects who we are today and where we are headed. It signals our ambition, our capabilities, and our unwavering focus on expanding access to medicines that make a meaningful difference in people's lives."Amneal Pharmaceuticals plans to introduce its Accessibility Index later this year, a platform designed to demonstrate real impact on affordability, availability, and innovation across its portfolio spanning complex generics, injectables, biosimilars, and specialty therapies.TheraTears, a subsidiary of Prestige Consumer Healthcare (NYSE: PBH), expanded its dry eye portfolio with two new products launching nationwide in February 2026: Eyelid Cleansing Wipes and Dry & Tired Preservative Free Lubricant Eye Drops. The preservative-free drops contain twice the hydrating ingredient of TheraTears' original formula and target consumers experiencing screen-related eye fatigue.The Eyelid Cleansing Wipes are formulated for gentle daily use with a non-stinging formula that removes irritants aggravating dry eye symptoms. Both products will be available at Amazon, Walgreens, and Walmart as part of the ophthalmologist-created brand's growing family of eye care solutions under Prestige Consumer Healthcare.Viking Therapeutics (NASDAQ: VKTX) reported fourth quarter and full-year 2025 financial results highlighting rapid progress across its obesity portfolio, ending the year with $706 million in cash to fund near-term catalysts including Phase 3 VANQUISH trials for subcutaneous VK2735. VANQUISH-1 enrollment exceeded 4,500 patients ahead of schedule, while VANQUISH-2 nears full enrollment."The past year was an exceptional year for Viking marked by rapid progress across our obesity portfolio," said Brian Lian, Ph.D., CEO of Viking Therapeutics. "We also expect to file an IND for our novel amylin agonist this quarter, expanding our obesity franchise."Viking Therapeutics plans to advance oral VK2735 into Phase 3 development in the third quarter of 2026, with maintenance dosing study results also expected in that period. The dual GLP-1/GIP agonist demonstrated up to 14.7% weight loss from baseline in its Phase 2 VENTURE trial.Insulet (NASDAQ: PODD) launched its Omnipod 5 Automated Insulin Delivery System across Saudi Arabia, Kuwait, Qatar, and the United Arab Emirates, bringing the tubeless wearable pump's global availability to 19 countries. The company simultaneously debuted Omnipod Discover, a proprietary data analytics platform designed to simplify glucose and insulin delivery insights for users and healthcare providers."We're proud to bring Omnipod 5 to a region where the unmet need is great," said Pat Crannell, Senior Vice President and International General Manager of Insulet. "It is even more meaningful and impactful with the inaugural introduction of Omnipod Discover, which simplifies data management and helps us create a world where diabetes demands less, every day."Insulet plans to launch Omnipod 5 in Spain later in 2026, followed by Greece and Croatia in the first half of 2027. Omnipod Discover will roll out to additional international markets after the Middle East introduction.Article Source: https://equity-insider.com/2025/12/19/what-comes-after-cigarettes-vapes-and-energy-drinks/ CONTACT:Equity Insider
info @acblanke1DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity-Insider.com is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). "). This article is being distributed for Maynard Communications ("MAY"), who has been paid a fee for an advertising campaign. MIQ has not been paid a fee for Doseology Sciences. Inc. advertising or digital media, but expects to be paid a fee from ("MAY"). There may be 3rd parties who may have shares of Doseology Sciences Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Doseology Sciences Inc., which were purchased as a part of a private placement. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Doseology Sciences Inc.; this is a paid advertisement, we currently own shares of Doseology Sciences Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.SOURCES:1. https://www.precedenceresearch.com/functional-beverages-market2. https://www.mordorintelligence.com/industry-reports/global-functional-food-market3. https://globalwellnessinstitute.org/press-room/press-releases/global-wellness-summit-releases-10-wellness-trends-for-2026/4. https://insights.citeline.com/hbw-insight/perspectives/consumer-health-and-wellness-market-outlook-what-trends-will-impact-self-care-in-2026-T7WQJYMDZJE4FLRJAEHVIT7REE/Logo - https://mma.prnewswire.com/media/2840019/5798142/Equity_Insider_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/accessible-health-platforms-gain-scale-across-6t-health-and-wellness-market-302687851.html
Original: Accessible Health Platforms Gain Scale Across $6T Health and Wellness Market
iHub News
4月前
Prestige Consumer Healthcare Q3 Revenue Beats Forecasts as Company Refines Full-Year OutlookFebruary 5, 2026 8:32 AM
IH Market News
Prestige Consumer Healthcare Inc. (NYSE:PBH) reported fiscal third-quarter results on Thursday showing revenue that exceeded analyst expectations, while earnings matched forecasts as the company continues addressing supply chain constraints.The company’s shares rose about 0.7% in after-hours trading following the earnings release.Prestige posted revenue of $283.4 million for the quarter ended December 31, 2025, beating analyst estimates of $281.12 million, although revenue declined 2.4% from $290.3 million recorded in the same period a year earlier. Adjusted earnings per share were $1.14, in line with analyst projections but below the $1.22 reported in the prior-year quarter.The decline in revenue was largely driven by weaker sales in the Ear & Eye Care segment, primarily due to supply limitations affecting the company’s Clear Eyes product line. The company noted that supply conditions showed sequential improvement during the quarter. Despite the challenges, quarterly revenue exceeded the company’s earlier internal guidance.“We exceeded our third quarter revenue outlook and delivered solid profitability in the quarter, which reflected the benefits of our diverse business model and strong financial profile,” said Ron Lombardi, Chief Executive Officer of Prestige Consumer Healthcare.During the quarter, Prestige completed its acquisition of eye care manufacturer Pillar5 Pharma, Inc., which the company expects will help alleviate supply shortages affecting Clear Eyes products. Prestige also repurchased approximately 0.8 million shares during the period at a total cost of $45.8 million.For fiscal 2026, the company narrowed its revenue outlook to approximately $1.1 billion, compared with its previous forecast range of $1.1 billion to $1.15 billion. The updated guidance is slightly below analyst consensus expectations of $1.11 billion. Prestige also revised its full-year earnings outlook, projecting earnings per share of around $4.54, compared with analyst estimates of $4.56.“Looking ahead we continue to rebuild our supply chain capacity for Clear Eyes and expect supply improvements in coming quarters to support long-term demand,” Lombardi added. “We are narrowing our fiscal 2026 net sales outlook to approximately $1.1 billion to reflect a continued challenging consumer environment.”The company maintained its free cash flow forecast of at least $245 million for fiscal 2026, underscoring its strong financial position despite ongoing market headwinds.Prestige Consumer Healthcare stock price
Original: Prestige Consumer Healthcare Q3 Revenue Beats Forecasts as Company Refines Full-Year Outlook
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
Penny Roger$
14年前
メールアドレスで登録
